Complex roles of cAMP–PKA–CREB signaling in cancer

Hongying Zhang¹, Qingbin Kong¹, Jiao Wang², Yangfu Jiang¹ and Hui Hua³*

Abstract
Cyclic adenosine monophosphate (cAMP) is the first discovered second messenger, which plays pivotal roles in cell signaling, and regulates many physiological and pathological processes. cAMP can regulate the transcription of various target genes, mainly through protein kinase A (PKA) and its downstream effectors such as cAMP-responsive element binding protein (CREB). In addition, PKA can phosphorylate many kinases such as Raf, GSK3 and FAK. Aberrant cAMP–PKA signaling is involved in various types of human tumors. Especially, cAMP signaling may have both tumor-suppressive and tumor-promoting roles depending on the tumor types and context. cAMP–PKA signaling can regulate cancer cell growth, migration, invasion and metabolism. This review highlights the important roles of cAMP–PKA–CREB signaling in tumorigenesis. The potential strategies to target this pathway for cancer therapy are also discussed.

Keywords: cAMP, PKA, CREB, Cancer

Background
Cell growth is tightly regulated by a variety of signal transduction pathways. Abnormal activation or inhibition of signal transduction pathways drives tumorigenesis. Posttranslational protein modifications, such as phosphorylation, ubiquitination, methylation and acetylation, are one of the important mechanisms that regulate cell signaling. Protein phosphorylation and dephosphorylation are regulated by various protein kinases and phosphatases, respectively. Abnormal or uncontrolled activation of protein kinases or phosphatases is very common in tumors, poising them as important targets for molecular targeted cancer therapeutics. As an inhibitor of the oncogenic kinase BCR–ABL, imatinib is the first kinase-targeted anticancer drug that has been successfully applied in the treatment of chronic myeloid leukemia [1]. Later on, inhibitors of protein kinases such as EGFR, ErbB2, MAPK, VEGFR and mTOR have been widely used in the treatment of a variety of common malignant tumors [2–5].

Cell signaling is often initiated by first messengers such as growth factors, hormones and ions, which trigger a series of signal transduction cascades via membrane receptors or intracellular receptors. This process involves multiple feedback mechanisms as well as a number of intracellular chemicals, known as the second messengers, such as cyclic adenosine monophosphate (cAMP), cGMP, calcium ions and so on [6]. In general, the production and distribution of these second messengers also need precise regulation. Abnormal production and distribution of these second messengers may contribute to carcinogenesis and tumor progression. The second messenger theory was first proposed by E. W. Sutherland in 1965. As a second messenger, cAMP is responsible for activation of the protein kinase A (PKA), exchange proteins directly activated by cAMP (Epac) and ion gated channel protein [7]. As one of the target proteins of PKA, cAMP response element binding protein (CREB) is an important transcription factor that regulates the expression of several genes including oncogenes c-Jun and cyclin D1 [8]. Notably,
cAMP–PKA–CREB signaling has both tumor-suppressive and tumor-promoting effects on cancer, depending on the tumor types and context.

**The generation and degradation of cAMP**

cAMP exists extensively in cells. Many hormones, neurotransmitters and other signaling molecules use it as an intracellular second messenger. Therefore, cAMP can directly regulate various biological processes or behaviors of cells, including cell metabolism, ion channel activation, gene expression, cell growth, differentiation and apoptosis [9]. The generation of cAMP is regulated in a G-protein-dependent or G-protein-independent manner. After extracellular ligands, such as PGE2, GLP-1 and β2 receptor agonists, bind to G-protein coupled receptors (GPCRs), Gα subunits are separated from Gβ and Gγ subunits, and then activate adenylyl cyclases (ACs), leading to the conversion of ATP into cAMP (Fig. 1) [10–12]. In addition, bicarbonate (HCO₃⁻) and calcium ions (Ca²⁺) induce cAMP synthesis by activating the soluble adenylyl cyclase (sAC) independent of G-proteins [13, 14]. In contrast, phosphodiesterases (PDEs) are responsible for the degradation of cAMP. So far, at least 22 PDEs have been identified [15]. The concentration of intracellular cAMP depends on the relative balance between adeny-lyl cyclases and phosphodiesterases.

**The molecular targets and roles of cAMP in cancer cell growth, migration and metabolism**

As shown in Fig. 1, the major targets of cAMP include PKA, Epac1 and Epac2, and nucleotide-gated ion channels. The cAMP binding domain of Epac can bind a cAMP molecule, resulting in conformational changes of the protein thereby exposing the active site in catalytic domain. As a guanosine exchange factor (GEF), Epac can promote Ras family proteins Rap1 and Rap2 to release GDP and bind GTP, leading to the activation of Rap1/2 [16]. Epac regulates multiple cell processes mainly through Rap-GEF dependent and Rap-GEF independent pathways, including migration and focal adhesion formation, morphogenesis, cardiac output, neurotransmitter release, glucose homeostasis, exocytosis, cell proliferation, cell differentiation and cell survival [16]. cAMP can also bind to some nucleotide-gated ion channels and regulate their functions, such as cyclic nucleotide gated ion channels (CNG) and hyperpolarization-activated cyclic nucleotide-gated channel (HCN) [6]. These channels are non-selective cation channels that can conduct calcium, sodium and potassium ions and change the cell membrane potential. Below, we shall focus on PKA as a classical target of cAMP.

![Fig. 1] cAMP signaling pathway. The generation of cAMP is regulated in a G-protein dependent manner by AC or G-protein independent manner by sAC. The degradation of cAMP is regulated by PDEs. cAMP can regulate multiple signaling pathways including ion channels, Epac, and PKA. R the regulatory subunit of PKA, C the catalytic subunit of PKA.
PKA is a tetramer enzyme consisting of two regulatory subunits (R) and two catalytic subunits (C) (Fig. 1). In mammals, there are four types of regulatory subunits, namely RIα, RIβ, RIIα and RIIβ. According to the different regulatory subunits, PKA can be classified into PKA type I (RIα2C2, RIβ2C2) and PKA type II (RIIα2C2, RIIβ2C2) [17]. The binding to two regulatory subunits of the inactive PKA tetramer by cAMP results in the release and activation of the catalytic subunits, phosphorylation of the serine and threonine residues in substrate proteins [18]. RIα and RIIα are widely distributed in different cells, while RIβ mainly exists in the brain, testis and lymphocytes, and RIIβ is expressed in the brain, fat, and some endocrine tissues [19]. The localization of the tetramer enzyme is also different. PKA type I are generally cytoplasmic, while PKA type II are specifically anchored in subcellular structures and compartments [20]. PKA anchored proteins (AKAPs) can bind to cytoskeleton proteins or organelles and to PKA regulatory subunits, thereby playing an important role in the distribution of PKA in cells and enabling PKA to park and concentrate key targets [21, 22]. PKA type I is overexpressed in a variety of primary tumors [23].

There are three types of PKA catalytic subunits, including Cα, Cβ and Cγ. Cα and Cβ are two major types and have multiple splice variants. This subtype diversity is an important mechanism for achieving the specificity of PKA signaling [24]. Once activated, PKA phosphorylates its substrates, such as CREB, Raf, Bad and GSK3 [25–27], and then regulates gene expression, cell survival and migration. Recent study indicates that PKA is an actomyosin contractility-regulated effector of cellular mechanotransduction and a regulator of mechanically guided cell migration [28]. PKA also phosphorylates CDC42 interacting protein 4 (CIP4), a coordinator of membrane deformation and actin polymerization, and promotes cancer cell invasion and metastasis [29]. Actually, the promotion of cancer cell invasion and metastasis by PKA may involve multiple PKA substrates. The focal adhesion kinase is another PKA target that mediates the promotion of cancer metastasis by cAMP [30]. In addition, PKA can phosphorylate and then inactivate the calmodulin-dependent protein kinase kinase-2 (CAMKK2) [31]. CAMKK2 plays important roles in energy homeostasis, insulin signaling and whole-body metabolism [32, 33]. Inhibition of CAMKK2 protects against prostate cancer, hepatocellular carcinoma (HCC) and metabolic disorders induced by a high-fat diet [34]. Moreover, PKA can reprogram lipid metabolism by inhibiting salt-inducible kinases, and then promote pancreatic tumorigenesis [35]. Meanwhile, PKA signaling cooperates with the epigenetic regulators JMJD3 and SIRT1 to activate β-oxidation-promoting genes [36]. There may be more and more metabolism-related targets of PKA to be discovered. Of note, activated PKA can feedback inhibit adenylyl cyclase (AC5 and AC6) and activate phosphodiesterase (PDE3 and PDE4) thereby lowering the levels of cAMP and maintaining cAMP homeostasis [12, 37].

The CREB family proteins are well-characterized PKA substrates. This family is a group of the basic leucine zipper (bZIP) superfamily transcription factors, including CREB, cAMP responsive element regulatory protein (CREM) and transcriptional activator 1 (ATF1). CREB, CREM and ATF1 form homodimers or heterodimers [38–40]. Both CREB and ATF-1 proteins are ubiquitously expressed, while CREM is mostly expressed in neuroendocrine tissues [40]. The CREB family proteins contain a kinase inducible domain (KID), two glutamate domains (Q1 and Q2), and a basic leucine zipper domain (bZIP). KID is a 60-amino acid fragment located in the central region of CREB, CREM and ATF1, which contains the PKA phosphorylation site (RRPSY) (Fig. 2) [41].

Phosphorylation of CREB Ser133 residue and ATF1 Ser63 residue is critical for the transcriptional activity of CREB and ATF1. Activated ATF1 and CREB can form homodimer or heterodimer, bind to the cAMP response element (CRE) in the promoter region of target genes and initiate genes transcription, thereby regulating cell differentiation, proliferation, apoptosis, metabolism, glucose homeostasis, hematopoiesis, immune response as well as neuronal activities such as memory and learning (Fig. 3) [42–44]. In addition...
to the major PKA kinase, other kinases such as RSK, MSK, AKT, and CAMKII/IV also directly phosphorylate CREB and ATF1 [45–50].

**The roles of cAMP–PKA–CREB signaling pathway in tumors**
cAMP–PKA–CREB signaling has paradoxical effects in tumors, acts as a tumor-suppressor or tumor-promoter in different tumor types (Table 1). The role of cAMP–PKA–CREB signaling pathway in liver cancer and other tumors is described below.

**Liver cancer**
Whereas some studies suggest that increasing cAMP levels may inhibit HCC cells growth [51–53], it has been reported that PKA promotes HCC invasion and metastasis by phosphorylating multiple substrates such as CIP4 [29]. Fibrolamellar hepatocellular carcinoma (FL-HCC) is a primary liver cancer that occurs mainly in children and young adults. 80%-100% FL-HCC patients have DNAJB1–PRKACA gene fusion, resulting in the deletion of a 400 kb gene fragment on chromosome 19 and the production of a chimeric protein that retains PKA kinase activity [54]. DNAJB1–PRKACA knock-in mice can develop tumors characteristics of FL-HCC [55]. In addition, PRKACA is overexpressed in about 80% of BAP1 gene (encoding BRCA1-associated protein 1)-mutated HCC, which exhibit similar clinical manifestations and histological characteristics to DNAJB1–PRKACA fusion-related FL-HCC [56]. PKA pathway dysfunction plays an important role in the development and progression of these two kinds of HCC. Hepatitis B virus (HBV) infection is a major risk factor for the development of HCC. HBV X protein plays an important role in HBV-related HCC. Mechanistically, HBVx can promote liver carcinogenesis through CREB-miR-3188 and ZHX2-Notch signaling pathway [57], promote HCC cell growth by activating CREB-YAP axis [58], and promote the invasion...
and metastasis of HBV-related HCC by up-regulating FOXM1 expression through Erk-CREB pathway [59]. Collectively, these studies indicate that the PKA-CREB pathway may promote HCC progression. Indeed, analysis of rat HCC tumors and paired normal liver samples showed significant increase in CREB and CREB phosphorylation levels in HCC [60].

However, the roles of cAMP in HCC appear to be somewhat paradoxical. As we described above, increasing cAMP levels by PDE inhibitors may arrest HCC cells growth. Treatment of HepG2 cells with cAMP analogues significantly reduce the transcription and protein levels of cyclin A and induce cell cycle arrest [61]. In addition, PDE4 inhibitor rolipram and DC-TA-46 can up-regulate the expression of p21, p27 and p53 and down-regulate cyclin A expression, thereby inhibiting the proliferation and promoting apoptosis of HepG2 cells [52]. In contrast, vasoactive intestinal peptide could reduce cAMP concentration, CREB expression and Ser133 phosphorylation, and inhibit Bcl-xL expression, leading to Huh7 cell apoptosis [62]. The versatile roles of cAMP in HCC may be due to the multiplicity of its targets with diverse functions. Hence, whether cAMP promotes or inhibits HCC may be context-dependent. The homeostasis in cAMP levels may be critical for HCC progression.

**Brain cancer**

The roles of the CREB-activating kinase PKA in brain tumors are also paradoxical. Several studies have shown that PKA plays a tumor-suppressive role in glioblastoma cell line A-172. Activation of PKA by increasing cAMP levels or supplying cAMP analogues (dcAMP and 8-Br-cAMP) can reduce the proliferation rate of A-172 cells, promote differentiation, and induce apoptosis [63]. Increasing the intracellular cAMP levels by rolipram, a PDE inhibitor, can up-regulate the expression of p21 and p27, and activate PKA and Epac1-Rap1 signaling, leading to A-172 cell growth arrest and apoptosis [64, 65]. cAMP pathway also plays anticancer role in medulloblastoma. Pituitary adenylyl cyclase inhibits the proliferation of medulloblastoma cells through PKA-Gli1 pathway [66], and neurociliary proteins inhibit the growth of medulloblastoma through PDE4D-PKA-Hedgehog pathway [67]. ARHGAP36 protein, a member of RhoGAP family,
can bind to PKA catalytic subunit and inhibit its activity, thereby activating Hedgehog pathway and promoting the growth of medulloblastoma [68]. The tumor-suppressive effects of cAMP and PKA may be mediated by Epa1c, Rap1 and Gli1, rather than CREB.

Phosphorylation of CREB can be directly inhibited by PTEN, an anticancer protein phosphatase that is frequently mutated or inactivated in many cancers, including the most aggressive types of brain cancer, glioblastoma multiforme and astrocytoma [69, 70]. PTEN deficiency can enhance CREB activity and induce the expression of PAX7, thereby promoting the conversion of human neural stem cells to glioblastoma stem-like cells [71]. In addition, CREB can reciprocally down-regulate PTEN. Tan et al. reported that CREB was highly expressed in clinical samples and cell lines of glioma, and CREB could inhibit PTEN expression through miR-23, thus promoting the development of glioma [72]. Moreover, EGFR can activate CREB through MAPK-RSK2 pathway, and then promote glioma cells growth and invasion [73].

Epidermal growth factor receptor (EGFR), EGFRvIII mutant and platelet derived growth factor receptor (PDGFR) can promote the development and invasion of glioblastoma through the PKA-Dock180 signaling pathway [74, 75]. Also, miR-33a enhances CAMP–PKA signaling by inhibiting PDE8A expression, thus promoting the growth and self-renewal of initial glioma stem cells [76]. In human glioblastoma cell line MGR3, activation of PKA leads to a significant increase in GSTP1 phosphorylation and activity, which may lead to drug resistance and treatment failure [77].

Lung cancer
In non-small cell lung cancer (NSCLC), there are significant up-regulation of CREB expression and phosphorylation in tumor tissues compared with adjacent normal tissues. Increased CREB expression is correlated with short survival period of patients [78]. cAMP could down-regulate SIRT6 expression and thus reduce the apoptosis of NSCLC cells induced by radiotherapy [79]. In the highly malignancy small cell lung cancer (SCLC), increased activity of CREB helps maintain its neuroendocrine characteristics and proliferation [80]. RGS17 is increased in 80% of lung cancer tissues compared with matched normal lung tissue and promotes cell proliferation through the cAMP–PKA–CREB pathway [81]. In addition, PKA-Smurf1-PIPKIγ signaling transduction promotes the progression of lung cancer in vivo [82]. cAMP–PKA–CREB pathway could regulate the hypoxia response in lung cancer cells [83]. PKA inhibitors H-89 and PKACA knockdown antagonize hypoxia-induced epithelial-mesenchymal transformation, cell migration, and invasion of lung cancer cells [84]. Moreover, oxidative stress plays an important role in the pathogenesis of lung diseases, including pulmonary fibrosis and lung cancer. Interactions among PKA, Erk1/2 and CREB mediate cell survival in oxidative stress [85].

Contrary to the inhibition of radiotherapy-induced NSCLC cell apoptosis by cAMP-Sirt6 pathway [79], cAMP–PKA–CREB pathway seems to play an anticancer role in radiotherapy. BALB/c mice pretreatment with forskolin could inhibit ATM and NF-κB by PKA-induced PP2A phosphorylation, resulting in an increase in radiotherapy-induced apoptosis [86]. In lung cancer cell line H1299, Gs protein promotes Bak expression through PKA-CREB-AP1 pathway and increases apoptosis induced by radiotherapy [87]. These studies suggest that the cAMP–PKA–CREB pathway may also exert opposite effects under different circumstances of the same type of tumor.

Prostate cancer
PKA subunit can be a biomarker to predict the response of prostate cancer to radiotherapy and chemotherapy. Analysis of 456 clinical prostate cancer specimens found that PKA RIα is highly expressed in 80 cases (17.5%), and PKA RIα overexpression is associated with poor efficacy of radiotherapy and short-term or long-term androgen deprivation therapy, distant metastasis and abnormal biochemical index [88]. In prostate cancer cell line PC3M cells, the overexpression of wild type PKA RIβ mutant type PKA RIα-P (functionally similar with PKA RIβ) leads to growth inhibition and apoptosis in vitro, and inhibits tumor growth in vivo [89]. Androgen receptor (AR) signaling is critical for prostate carcinogenesis. Testosterone directly stimulates GPR56 and then activates the cAMP/PKA pathway, which promotes AR signaling [90]. PKA also phosphorylates the Thr89 residue in HSP90, leading to the release of AR from HSP90 and the binding of AR to HSP27, which transfers AR into the nucleus to transactivate its targets [91]. In addition, PKA signaling pathway is involved in the neuroendocrine differentiation of prostate cancer, an early marker for the development of androgen independence [92, 93]. Moreover, high expressions of osteocalcin and osteosardin in androgen independent prostate cancer cell line C4-2B are dependent on the cAMP–PKA signaling pathway [94]. PAK4 can be activated by cAMP–PKA to enhance CREB transcription activity independent of phosphorylation at Ser132 residue, and PAK4 knockdown in PC-3 and DU145 cells inhibit tumor formation in nude mice [95]. Moreover, RGS17 is overexpressed in prostate cancer samples and promotes cell proliferation through the cAMP–PKA–CREB pathway [81]. In addition, it has been reported that depression and behavioral stress can
accelerate the progression of prostate cancer through PKA kinase [30, 96].

**Ovarian cancer**

About 54% of epithelial-derived human ovarian tumors in tissue microarray have moderate or high levels of CREB expression, while no expression was observed in normal ovarian samples. Knockdown of CREB expression significantly reduces proliferation of ovarian cancer cells, but had no effect on apoptosis [97]. Epithelial ovarian cancer is one of the most deadly gynecologic malignant tumors. PKA R1α is highly expressed in epithelial ovarian cancer [98]. During metastatic spread of epithelial ovarian cancer cell line SKOV3, extracellular matrix invasion needs PKA activity and AKAPs anchor, and inhibition of PKA activity or PKA R1 and R2 anchor can block matrix invasion [99]. In addition, PKA reduces the intensity of tight junction in epithelial ovarian cancer cell line OVCA433 by phosphorylating claudin-3 [100]. Also, gonadotropin promotes the metastasis of epithelial ovarian cancer cells through PKA and PI3K pathways [101]. Whereas the above-mentioned studies suggest that PKA-CREB plays a tumor-promoting role in epithelial ovarian cancer, one study suggests that PKA can phosphorylate EZH2 at Thr372 residue, leading to mitochondrial dysfunction, the binding of EZH2 to STAT3 and then inhibiting STAT3 phosphorylation and epithelial ovarian cancer cell growth [102].

**Breast cancer**

Overexpression of R subunit especially RI of PKA is associated with cell proliferation in normal breast, malignant transformation of breast epithelial cells, poor prognosis of breast cancer, and tolerance to anti-estrogen therapy. Recent study demonstrates that nuclear localization of activated PKA is correlated with breast cancer metastasis [103]. Integrin α9 maintains the stability of β-catenin through ILK/PKA/GSK3 signaling and, thereby promotes the growth and metastasis of triple negative breast cancer cells [104]. Moreover, successful anti-estrogen therapy is associated with reduced RI mRNA expression, and RI antisense oligonucleotides can reduce the growth rate of breast cancer cells [105]. In estrogen receptor positive breast cancer, PKA-induced ERα Ser305 phosphorylation and PAK1 are associated with tamoxifen resistance and breast cancer progression [106, 107]. In Her-2 positive breast cancer cells, PKA activation is associated with trastuzumab resistance [108]. In addition, cAMP–PKA–CREB pathway also plays an important role in the metabolic regulation of breast cancer. Serotonin promotes mitochondrial biosynthesis through the AC-PKA pathway in breast cancer cells [109]. Cytoplasmic G-protein coupled estrogen receptor promotes aerobic glycolysis through cAMP–PKA–CREB pathway [110]. Contrary to above studies, it is reported that IL-24 induces breast cancer cells apoptosis by activating TP53 and endoplasmic reticulum stress through PKA [111]. Hence, PKA may also have paradoxical roles in breast cancer depending on the context.

**Leukemia**

The role of cAMP is quite different in diverse types of lymphoma. PDE4 inhibitors block intracellular TLR signaling and promote apoptosis of chronic lymphocytic leukemia (CLL) cells through increasing cAMP concentration [112, 113]. Interestingly, PDE4 inhibitors induce apoptosis in B cell CLL but not in T cell CLL or normal circulating hematopoietic cells, probably due to that PDE4 inhibitors only augment glucocorticoid receptor and cAMP levels in B cell CLL [114, 115]. cAMP–PKA could promote apoptosis through mitochondria dependent pathways, reducing expression of anti-apoptotic proteins Bcl-2 and survivin, and increasing expression of pro-apoptotic protein Bax in lymphoma cells [116–118]. The chemokines CXCR4 and CXCL12 released from the microenvironment can bind to Gαi-conjugated GPCRs on CLL cells, reducing cAMP synthesis and increasing survival rate of CLL cells [119, 120]. PDE7B is overexpressed in CLL, and inhibitors of PDE7 (BRL-50481 and IR-202) and a dual PDE4/PDE7 inhibitor IR-284 increase apoptosis of CLL cells, which is attenuated by PKA inhibition [121].

CREB is overexpressed in the bone marrow of most leukemia cell lines and patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) [122]. Previous studies also show that CREB is highly expressed in the majority of myeloid leukemia cells in AML patients and associated with poor prognosis [123]. The jmjd3/UTX inhibitor GSKJ4 can promote CREB degradation and inhibit AML cell growth [123]. Overexpression of CREB can promote AML cells proliferation by up-regulating cyclin A1 expression. In addition, the CREB transgenic mice shows myeloproliferative diseases but not leukemia, suggesting that CREB is involved in the leukemia phenotype during the leukemia germination, but is not sufficient to completely transform into leukemia [124]. In contrast, cAMP can protect acute promyelocytic leukemia cells from apoptosis induced by arsenic trioxide and anthracyclines [124]. In AML cell line IPC-81, cAMP can induce apoptosis through up-regulation of Bim by CREB and CDK [125].

**Other tumors**

The mRNA and protein levels of PKA R1α and AKAP10 are significantly increased in colorectal cancer tissues, correlating with invasion depth, differentiation degree
and short survival [126]. Type-I insulin-like growth factor receptor (IGF-IR) is tightly involved in tumorigenesis and drug resistance [127]. IGF-IR signaling induces ezrin phosphorylation at Thr^{567} residue and thereby promotes cAMP-dependent PKA activation and colorectal cancer cell survival [128]. Overexpression of PKA Rα and AKA10 in several colorectal cancer cell lines is directly correlated to metastasis. In addition, the resistance of colorectal cancer cells to a selective MEK1/2 inhibitor selumetinib is induced by PKA activation [129], and the resistance of colorectal cancer cells to methotrexate can be induced by cAMP signaling [130]. PKA antagonists could inhibit the nuclear translocation of β-catenin and expression of c-myc and COX2 in APC mutant colorectal cancer, thereby inhibiting tumor development [131].

Immunohistochemical experiments found that normal melanocytes did not express PKA Rλ proteins, but it is highly expressed in human melanoma samples and some melanoma cell lines. RII activation or Rλ silence can inhibit proliferation and increase caspase 3-promoted apoptosis [132]. PKA can promote the migration of melanoma cells. Studies have found that hypoxia can induce the expression of scaffold protein AKA12 in melanoma, and PKA-regulated phosphorylation during hypoxia is dependent on the presence of AKA12. Inactivation of AKA12 leading to the reduction of tumor growth, migration, and invasion in melanoma mouse models [133]. PKA pathway also plays an important role in the synthesis of melanin. Diethylstilbestrol can promote melanin production through cAMP–PKA mediated up-regulation of tyrosinase and MITF in mouse melanoma cell line B16 [134], and gingerol inhibits melanin production by down-regulating MAPK and PKA [135].

**Targeting cAMP–PKA pathway for cancer therapy**

Given the involvement of cAMP–PKA pathway in tumor progression, targeting this pathway may be a potential strategy to treat cancer. The cAMP analogue 8-Cl-cAMP, also known as tacladesine, can inhibit the growth of colorectal cancer, breast cancer, lung cancer, fibrosarcoma and leukemia in vitro and in vivo [136, 137]. Due to the different binding affinity with PKA R subunits, 8-Cl-cAMP can down-regulate Rλα and induce RIIβ expression [136]. Some researchers have proposed that 8-Cl-cAMP may also exert PKA-independent anti-tumor effects through its metabolite 8-Cl-adenosine and AKT2–PKBβ pathway [138, 139]. Although its anti-tumor mechanisms have not been fully elucidated, 8-Cl-cAMP has been tested in phase II clinical trials in patients with multiple myeloma and in phase I clinical trials in patients with metastatic colorectal cancer, but the results of these trials have not been disclosed (Table 2).

Since cAMP has tumor suppressive roles in some types of cancer, increasing cAMP levels may inhibit these types of tumors. PDE inhibitors can suppress the depletion of cAMP. Notably, PDE inhibitors have been widely used in clinic to treat cardiovascular, respiratory and psychiatric diseases. The PDE3 inhibitors amrinone and milrinone are used as cardiotonic drugs. PDE4 inhibitor rolipram is a new anti-inflammatory drug for asthma treatment. PDE5 inhibitor sildenafil is a preferred drug for erectile dysfunction treatment [140]. In addition, some flavonoids natural products can also inhibit PDEs [141]. These PDE inhibitors may be repurposed to treat cancers in which cAMP has tumor-suppressive roles. In contrast, PDE activators may be developed to treat cancers that are promoted by cAMP signaling. Recently, a small-molecule compound that allosterically activates PDE4 long isoforms has been developed [142]. This prototypical PDE4 activator compound is able to reduce intracellular cAMP levels and inhibit cyst formation in the kidney [142]. It remains to know whether such kinds of PDE activators may be repurposed to treat some types of cancer.

Antisense oligonucleotide targeting the N-terminal PKA Rλα is another choice to interfere with PKA signaling. PKA Rλα knockdown leads to compensative expression of RIIβ and then inhibits tumor growth in a wide variety of tumor models [143]. The antisense

| Identifier | Title | Cancer type | Locations |
|------------|-------|-------------|-----------|
| NCT00004902 | Tocladadine in treating patients with recurrent or refractory multiple myeloma | Multiple myeloma and plasma cell tumor | Robert H. Lurie Comprehensive Cancer Center, Northwestern University Chicago, Illinois, United States |
| NCT00021268 | Tocladadine in treating patients with recurrent or progressive metastatic colorectal cancer | Colorectal cancer | Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California, United States |
| NCT00021268 | Docetaxel and GEM 231 in treating patients with recurrent or refractory solid tumors | Unspecified adult solid tumor | Albert Einstein Comprehensive Cancer Center Bronx, New York, United States |
| NCT0004863 | Paclitaxel and GEM 231 in treating patients with recurrent or refractory solid tumors | Unspecified adult solid tumor | Albert Einstein Comprehensive Cancer Center Bronx, New York, United States |
oligonucleotide GEM231 has been evaluated in two phase I clinical trials (Table 2). The results of the phase I clinical trial of GEM231 in combination with docetaxel showed that the overall incidence of grade 3 adverse reactions, including fatigue, elevated aminotransferase, neutropenia and altered mental status, was 75% in 20 patients with refractory solid tumors during 39 cycles of treatment [144]. No subsequent clinical trial has been reported.

CREB may also be a target for cancer therapy. Currently, there is no specific CREB inhibitor. The small molecule XX-650-23 blocks the interaction between CREB and its co-activator CBP (CREB-binding protein) and then abrogates CREB-responsive gene expression, leading to AML cells apoptosis and cell-cycle arrest [145, 146]. Another feasible strategy is to downregulate CREB expression. Previous study demonstrates that GSKJ4, the histone lysine demethylases JMJD3/UTX inhibitor, can induce CREB degradation and inhibit AML cell growth [123]. Given that JMJD3/UTX have multiple targets, GSKJ4 may also inhibit cancer cell growth by targeting proteins other than CREB. Since CREB may be activated by CAMK in some types of cancer, inhibition of CAMK may be an alternative strategy to suppress CREB [147].

Although there are some PKA inhibitors that have tumor-suppressive effects in preclinical studies, no small-molecule PKA inhibitors have been tested in clinical trials. It warrants further research to develop more small-molecule drugs targeting PKA and/or CREB, and evaluate their safety and efficacy in cancer therapy. In addition, repurposing some drugs that can act on PKA and CREB may be valuable to cancer therapy.

Concluding remarks

cAMP signaling pathway is evolutionarily conserved and plays key roles in major physiological and pathological processes. The functions of cAMP signaling in tumors depend on cell type and specific environment. In many types of human tumors, cAMP–PKA–CREB pathway plays a tumor-promoting role. The abnormal activation of this pathway and its interaction with other signaling pathways are closely related to tumorigenesis, invasion, metastasis and drug resistance. In contrast, cAMP and CREB also have tumor-suppressive roles in some types of tumors, such as medulloblastoma and non-Hodgkin’s lymphoma [148–150]. While cAMP may inhibit tumor progression through downregulating cyclin A, Erk or other targets, PKA also reportedly inhibits some tumor-suppressive effects in preclinical studies, no small-molecule PKA inhibitors have been tested in clinical trials. It warrants further research to develop more small-molecule drugs targeting PKA and/or CREB, and evaluate their safety and efficacy in cancer therapy. In addition, repurposing some drugs that can act on PKA and CREB may be valuable to cancer therapy.
3. Qin S, Li A, Yi M, Yu S, Zhang M, Wu K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol. 2019;12:27.

4. Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol. 2018;834:188–96.

5. Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y. Targeting mTOR for cancer therapy. J Hematol Oncol. 2019;12:71.

6. Fajardo A, Piazza G, Tinsley H. The role of cyclic nucleotide signaling pathways in cancer: targets for prevention and treatment. Cancers. 2014;6:436–58.

7. Sassone-Corsi P. The cyclic AMP pathway. Cold Spring Harb Perspect Biol. 2012;4:a001148.

8. Steven A, Friedrich M, Jank P, Heimer N, Budczies J, Denkert C, et al. Anti-cancer treatments. Endocr Relat Cancer. 2004;11:51–68.

9. Chin KV, Yang WL, Ravatn R, Kita T, Reitman E, Vettori D, et al. Reinvesting the wheel of cyclic AMP: novel mechanisms of cAMP signaling. Ann NY Acad Sci. 2002;968:49–64.

10. Kimple ME, Keller MP, Rabaglia MR, Pasker RL, Neuman JC, Truchan JM, et al. Mechanism of inhibition of Raf-1 by protein kinase A. Mol Cell Biol. 2007;27:5216–27.

11. Ali DC, Naveed M, Gordon A, Majeed F, Saeed M, Ogbuke MI, et al. Novel isozymes of cAMP-dependent protein kinase exist in human cells due to formation of R1 alpha-R1 beta heterodimeric complexes. J Biol Chem. 1993;268:21726–83.

12. Taskén K, Skålhegg BS, Solberg R, Andersson KB, Taylor SS, Lea T, et al. Novel isozymes of cAMP-dependent protein kinase exist in human cells due to formation of R1 alpha-R1 beta heterodimeric complexes. J Biol Chem. 1993;268:21726–83.

13. Kleinboelting S, Diaz A, Moniot S, van den Heuvel J, Weyand M, Levin LR, et al. Crystal structures of human soluble adenyl cyclase reveal mechanisms of catalysis and of its activation through bicarbonate. Proc Natl Acad Sci USA. 2014;111:3727–32.

14. Litvin TN, Kamenetsky M, Zarifyan A, Buck J, Levin LR. Kinetic properties of ‘soluble’ adenyl cyclase. Synergism between calcium and bicarbonate. J Biol Chem. 2003;278:15922–6.

15. Omon K, Koteja J. Overview of PDEs and their regulation. Circ Res. 2007;100:309–27.

16. Formoso K, Lezoualc’h F, Milet-Perez J. Role of EPAC1 signalosomes in cell fate: friends or foes? Cells. 2020;9:E1954.

17. Skålhegg KS, Zhou H, Mahklouf GM. PKA-dependent activation of PDE3A and PDE4 and inhibition of adenyl cyclase V/VI in smooth muscle. Am J Physiol Cell Physiol. 2002;283:C508–18.

18. Montminy MR, Biezak T, binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene. Nature. 1987;328:175–8.

19. Hai TW, Liu F, Allegretto EA, Karin M, Green MR. A family of immunologically related transcription factors that includes multiple forms of ATF and AP-1. Genes Dev. 1988;2:1216–26.

20. Foulkes NS, Botelli E, Sassone-Corsi P. CREB gene: use of alternative DNA-binding domains generates multiple antagonists of cAMP-induced transcription. Cell. 1991;64:739–49.

21. Sandoval S, PigaZZi M, Sakamoto KM. CREB: a key regulator of normal and cancer cell fate. J Mol Cell Biol. 2018;20:811–22.

22. Seok S, Kim YC, Byun S, Choi S, Xiao Z, Iwamori N, et al. Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid β-oxidation. J Clin Invest. 2018;128:3144–59.

23. Murthy KS, Zhou H, Mahklouf GM. PKA-dependent activation of PDE3A and PDE4 and inhibition of adenyl cyclase V/VI in smooth muscle. Am J Physiol Cell Physiol. 2002;283:C508–18.

24. Hao TX, Li PY, Li HC, Cao QH, Zhao DD, Zhou JR, et al. Depression promotes prostate cancer invasion and metastasis via a sympathetic-cAMP–F AK signaling pathway. Oncogene. 2019;38:2953–66.

25. Langendorf CG, O’Brien MT, Ngoei KRW, McAloon LM, Dhagat U, Hoque A, et al. CaMKII is inactivated by cAMP–PKA signaling and 1–4–3 adaptor proteins. J Biol Chem. 2020. https://doi.org/10.1074/jbc.RA120 013756.

26. Marcelo KL, Ribat T, Means CR, Tisemlczon A, Stevens RD, Ilkayeva O, et al. Research resource: roles for calcium/calmodulin-dependent protein kinase 2 (CaMKII) in systems metabolism. Mol Endocrinol. 2016;30:557–72.

27. Jensen B, Brennesvik E0, Lai YC, Shepherd PR. GSK-3βeta regulation in skeletal muscles by adrenaline and insulin: evidence that PKA and PKB regulate different pools of GSK-3. Cell Signal. 2007;19:204–10.

28. McKenzie AJ, Svec KV, Williams TF, Howe AK. Protein kinase A activity is regulated by actomyosin contractility during cell migration and is required for durotaxis. Mol Biol Cell. 2020;31:45–58.

29. Tonucci FM, Almada E, Borini-Etichetti C, Pariani A, Hidalgo F, Rico MJ, et al. Identification of a CIP4 PKA phosphorylation site involved in the regulation of cAMP receptor adaptor proteins. Eur J Pharmacol. 2017;794:1–7.
50. Feliciano DM, Edelman AM. Repression of Ca\textsuperscript{2+}/calmodulin-dependent protein kinase IV signaling accelerates retinoic acid-induced differentiation of human neuroblastoma cells. J Biol Chem. 2009;284:26466–81.

51. Massimi M, Ragusa F, Cardarelli S, Giorgi M. Targeting cyclic AMP signal- ing in hepatocellular carcinoma. Cells. 2019;8:1511.

52. Massimi M, Cardarelli S, Galli F, Gudiard MF, Ragusa F, Panera N, et al. Increase of intracellular cyclic AMP by PDE4 inhibitors affects HepG2 cell cycle progression and survival. J Cell Biochem. 2017;118:1401–11.

53. Peng T, Gong J, Yin Y, Zhou Y, Tong R, Wei X, et al. Inhibitors of phospho- diesterase as cancer therapeutics. Eur J Med Chem. 2018;150:742–56.

54. Graham JP, Jin L, Knudtson DK, Kof-Nelson SM, Greipp PT, Waldburger N, et al. DNAJB1–PRKACA is specific for fibrolamellar carcinoma. Mod Pathol. 2015;28:822–9.

55. Engelholm LH, Riaz A, Serra D, Dagnäes-Hansen F, Johansen JV, Santonio-Rugiu E, et al. CRISPR/Cas9 engineering of adult mouse liver demonstrates that the Dnajb1–Prkaca gene fusion is sufficient to induce tumors resembling fibrolamellar hepatocellular carcinoma. Gastroen- terology. 2017;153:1662–73.

56. Hirsch T, Negulescu A, Gupta B, Caruso S, Nobleb B, Couchy G, et al. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. J Hepatol. 2020;72:924–36.

57. Zhou DJ, Deng Y, Liang HF, Jiaode JC, Liu FY. Hepatitis B virus X protein promotes CREB-mediated activation of miR-188 and Notch signaling in hepatocellular carcinoma. Cell Death Differ. 2017;24:1577–87.

58. Zhang T, Zhang J, You X, Liu Q, Du Y, Gao Y, et al. Hepatitis B virus X pro- tein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells. Hepatology. 2012;56:2051–9.

59. Xia L, Huang W, Tian D, Zhu H, Zhang Y, Hu H, et al. Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma. J Hepatol. 2012;57:600–12.

60. Kovac SJ, Price JA, Shaw CM, Theodorakis MG, Micklilop H. Role of cyclic-AMP-response element binding (CREB) proteins in cell proliferation in a rat model of hepatocellular carcinoma. J Cell Physiol. 2006;206:411–9.

61. Lee J, Choi YH, Nguyen R, Kim J-S, Lee SJ, Trepel JB. Cyclic AMP induces inhibition of cyclin A expression and growth arrest in human hepatoma cells. Biochim Biophys Acta. 1999;1449:261–8.

62. Hara M, Takeba Y, Iiri T, Ohta Y, Ootaki M, Watanabe M, et al. Vasointestinal peptide increases apoptosis of hepatocellular carcinoma by the Ser/Thr protein kinases, cAMP-dependent protein kinase and protein kinase C, in glioblastomas. Cancer Res. 2004;64:9131–8.

63. Shaikh D, Zhou Q, Chen T, Ibe JCF, Raj JU, Zhou G. cAMP-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet-derived-growth factor receptor alpha. Neuro Oncol. 2015;17:832–42.

64. Wang H, Sun T, Hu J, Zhang R, Rao Y, Wang S, et al. mir-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways. J Clin Invest. 2014;124:4489–502.

65. Lo HW, Antoun GR, Ali-Orsan F. The human glutathione S-transferase P1 protein is phosphorylated and its metabolic function enhanced by the Ser/Thr protein kinases, cAMP-dependent protein kinase and protein kinase C, in glioblastomas. Cancer Res. 2004;64:9131–8.

66. Li H, Xiao N, Wang Y, Ren C, Yan P, Wu W, et al. Smurf1 regulates protein kinase is essential for glioma growth and invasion stimulated by platelet-derived-growth factor receptor alpha. Neuro Oncol. 2015;17:832–42.

67. Li H, Xiao N, Wang Y, Ren C, Yan P, Wu W, et al. Smurf1 regulates protein kinase is essential for glioma growth and invasion stimulated by platelet-derived-growth factor receptor alpha. Neuro Oncol. 2015;17:832–42.

68. Lee J, Choi YH, Nguyen R, Kim J-S, Lee SJ, Trepel JB. Cyclic AMP induces inhibition of cyclin A expression and growth arrest in human hepatoma cells. Biochim Biophys Acta. 1999;1449:261–8.

69. Hara M, Takeba Y, Iiri T, Ohta Y, Ootaki M, Watanabe M, et al. Vasointestinal peptide increases apoptosis of hepatocellular carcinoma by the Ser/Thr protein kinases, cAMP-dependent protein kinase and protein kinase C, in glioblastomas. Cancer Res. 2004;64:9131–8.

70. Li H, Xiao N, Wang Y, Ren C, Yan P, Wu W, et al. Smurf1 regulates protein kinase is essential for glioma growth and invasion stimulated by platelet-derived-growth factor receptor alpha. Neuro Oncol. 2015;17:832–42.

71. Duan S, Yuan G, Liu X, Ren R, Li J, Zhang W, et al. PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype. Nat Commun. 2015;6:10068.

72. Tan X, Wang S, Zhu L, Wu C, Yin B, Zhao J, et al. CAMP response element-binding protein promotes gliomagenesis by modulating the expression of oncogenic microRNA-23a. Proc Natl Acad Sci USA. 2012;109:15805–10.

73. Gampe K, Bring MS, Momma S, Goltz M, Zimmermann H. cAMP induces CREB and ERK activation at the wall of the mouse lateral ventricles. Brain Res. 2011;1376:31–41.

74. Feng H, Hu B, Yuori K, Sarkaria JN, Fumari FB, Cavenese WK, et al. EGFR/PI3K stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180. Oncogene. 2014;33:2504–12.

75. Feng H, Li Y, Yin Y, Zhang W, Hou Y, Zhang L, et al. Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet-derived-growth factor receptor alpha. Cell Death Differ. 2011;349:149–57.

76. Shaikh D, Zhou Q, Chen T, Ibe JCF, Raj JU, Zhou G. cAMP-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet-derived-growth factor receptor alpha. Neuro Oncol. 2015;17:832–42.

77. James MA, Lu Y, Liu Y, Viskis HG, You M. RGSI7, an overexpressed gene in human liver and prostate cancer, induces tumor cell proliferation through the cyclic AMP–PKA–CREB pathway. Cancer Res. 2009;69:2108–16.

78. Li H, Xiao N, Wang Y, Wang R, Chen Y, Pan W, et al. Smurf1 regulates lung cancer cell growth and migration through interaction with and ubiquitination of PIKfyve. Oncogene. 2017;36:6668–80.

79. Pullamsetti SS, Banat GA, Schmoll A, Szibor M, Pomagruk D, Hanje Z, et al. Phosphodiesterase-4B promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF. Oncogene. 2013;32:1121–34.

80. Shaikh D, Zhou Q, Chen T, Ibe JCF, Raj JU, Zhou G. cAMP-dependent protein kinase is essential for hypoxia-mediated epithelial-mesenchy- mal transition, migration, and invasion in lung cancer cells. Cell Signal. 2012;24:2396–406.

81. Barlow CA, Kitipongsapattana K, Siddiqui N, Roe MW, Mossman BT, Lounsbury KM. Protein kinase A-mediated CREB phosphorylation is an oxidant-induced survival pathway in alveolar type II cells. Apoptosis. 2008;13:681–92.

82. Cho EA, Kim EJ, Kwak SJ, Juhn YS. cAMP signaling inhibits radiation- induced ATM phosphorylation leading to the augmentation of apoptosis in human lung cancer cells. Mol Cancer. 2014;13:36.

83. Choi YJ, Kim SY, Oh JM, Juhn YS. Stimulatory heterotrimeric G protein augments gamma ray-induced apoptosis by up-regulation of Bax expression via CREB and AP-1 in H1299 human lung cancer cells. Exp Mol Med. 2009;41:592–600.

84. Pollack A, Bae K, Khor LY, Al-Saleem T, Hammond ME, Venkatesan V, et al. The importance of protein kinase A in prostate cancer: role in patient outcome in Radiation Therapy Oncology Group trial 92–02. Clin Cancer Res. 2009;15:5478–84.

85. Neary CL, Nesterova M, Cho YS, Cheadle C, Becker KG, Cho-Chung YS. Protein kinase A isozyme switching: eliciting differential cAMP signaling in prostate and tumor reversion. Oncogene. 2004;23:8947–56.

86. Singh JP, Dagar M, Dagar G, Kumar S, Rawal S, Sharma RD, et al. Activation of GPR36, a novel adhesion GPCR, is necessary for nuclear andro- gen receptor signaling in prostate cells. PLoS ONE. 2015;10:e0226056.
91. Dagar M, Singh JP, Dagar G, Tyagi RK, Bagchi G. Phosphorylation of HSP90 by protein kinase A is essential for the nuclear translocation of androgen receptor. J Biol Chem. 2019;294:8699–710.
92. Deeble PD, Murphy DJ, Parsons SJ, Cox ME. Interleukin-6- and c-AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol. 2001;21:8471–82.
93. Cox ME, Deeble PD, Bissonette EA, Parsons SJ. Activated 3'5'-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line. J Biol Chem. 2000;275:13812–8.
94. Huang WC, Xie Z, Konaka H, Sodek J, Zhuo HE, Chung LW. Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway. Cancer Res. 2005;65:2303–13.
95. Park MH, Lee HS, Lee CS, You ST, Kim DJ, Park BH, et al. p21-Activated kinase 4 promotes prostate cancer progression through CREB. Oncogene. 2013;32:2475–82.
96. Hassan S, Karpeva Y, Baid D, Yancey D, Pullkuth A, Flores A, et al. Behavioral stress accelerates prostate cancer development in mice. J Clin Invest. 2013;123:874–86.
97. Linnerth NM, Greenaway JB, Petrik JJ, Moorehead RA. cAMP response element-binding protein is expressed at high levels in human ovarian adenocarcinoma and regulates ovarian tumor cell proliferation. Int J Gynecol Cancer. 2008;18:1248–57.
98. Mcdaid HM, Cairns MT, Atkinson RJ, Mcalere S, Harris PD, Gilmore P. Increased expression of the Ralalpha subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer. Br J Cancer. 1999;79:933–9.
99. McKenzie AJ, Campbell SL, Howe AK. Protein kinase A activity and anchoring are required for ovarian cancer cell migration and invasion. PLoS ONE. 2011;6:e26552.
100. D'souza T, Agarwal R, Morin PJ. Phosphorylation of claudin-3 at threonine 484 by the γ2 subunit of PKA regulates cell proliferation and anchorage-independent growth in ovarian cancer. Br J Cancer. 2011;105:1680–7.
101. Mckenzie AJ, Campbell SL, Howe AK. Protein kinase A activity and anchoring are required for ovarian cancer cell migration and invasion. PLoS ONE. 2011;6:e26552.
102. O'connell G, Poon AH, Chou JY, Harte C, Mccann C, O'connor P, et al. Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity. Oncogene. 2018;37:3589–600.
103. Paul MR, Pan TC, Pant DK, Shih NN, Chen Y, Harvey KL, et al. Genetic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets. J Clin Invest. 2020;130:4252–65.
104. Wang Z, Li Y, Xiao Y, Lin H-P, Yang P, Humphries B, et al. Integrin α9 depletions promote B-catenin degradation to suppress triple-negative breast cancer tumor growth and metastasis. Int J Cancer. 2019;145:2767–80.
105. Miller WR. Regulatory subunits of PKA and breast cancer. Ann NY Acad Sci. 2002;968:37–48.
106. Kok M, Zwart W, Holm C, Fles R, Haupmann M, Van’t Vleit LJ, et al. PKA-induced phosphorylation of Ero1α at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res Treat. 2011;125:1–12.
107. Hua H, Zhang H, Kong Q, Jiang Y. Mechanisms for estrogen receptor expression in human cancer. Exp Hematol Oncol (2020) 9:32.
108. Moody SE, Schinzel AC, Singh S, Izzo F, Strickland MR, Luo L, et al. PRRKCA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. Oncogene. 2015;34:2061–71.
109. Sola-Penna M, Paixao LP, Branco JR, Ochiini AC, Albanese JM, Mundim DM, et al. Serotonin activates glycolysis and mitochondrial biogenesis in human breast cancer cells through activation of the Jak1/STAT5/ERK1/2 and adenylylate cyclase/PKA, respectively. Br J Cancer. 2020;122:194–208.
110. Yu T, Yang G, Hou Y, Tang X, Wu C, Xu XA, et al. Cytoplasmic GPER translocation in cancer-associated fibroblasts mediates cAMP/PKA/CREB/glycylcic acid to confer tumor cells with multidrug resistance. Oncogene. 2017;36:2317–45.
111. Peraudella L, Ming J, Zhong J, Zhang X, Francis A, Mendez M, Muharam H, et al. IL-24 promotes apoptosis through cAMP-dependent PKA pathways in human breast cancer cells. Int J Mol Sci. 2018;19:3561.
112. Kim DH, Lerner A. Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. Blood. 1998;72:2484–94.
113. Tan Y, Watkins AA, Freeman BB, Meyers JA, Rifkin IR, Lerner A. Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells. J Immunol. 2015;194:101–12.
114. Meyers JA, Taverna J, Chaves J, Makkijie A, Lerner A. Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells. Clin Cancer Res. 2007;13:4920–7.
115. Meyers JA, Su DW, Lerner A. Chronic lymphocytic leukemia and B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors. J Immunol. 2009;182:5400–11.
116. Zambon AC, Zhang L, Minovitsky S, Kanter JR, Prabhakar S, Salomonis N, et al. Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A. Proc Natl Acad Sci USA. 2005;102:8561–6.
117. Zhang L, Zambon AC, Vranizan K, Pothula K, Conklin BR, Insel PA. Gene expression signatures of cAMP/protein kinase A (PKA)-promoted, mitocho-ndrial-dependent apoptosis. Comparative analysis of wild-type and cAMP-deathless S49 lymphoma cells. J Biol Chem. 2008;283:4304–13.
118. Maram尼-Matsuda M, Moyer D, Molandor P, Furey-Dumazet H, Mart G, Bestard F, et al. Long-life chronic lymphocytic leukemia cells: role of cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc Natl Acad Sci U.S.A. 2008;105:19532–7.
119. Illiano M, Conte M, Salzillo A, Ragone A, Spina A, Nebbioso A, et al. The cAMP/PKA signaling in chronic lymphocytic leukemia B cells prevents spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96:655–65.
120. Burger JA, Tsukada T, Menger M, Zambon AC, Vranizan K, Pothula K, Dell’acqua M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2002;99:2657–9.
121. Zhang L, Murray F, Zahn A, Kanter JR, Chou D, Suda R, et al. Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7β in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2008;105:19532–7.
122. Sanada A, Seno H, Poortvallah A, Zand H. cAMP protects acute promyelocytic leukemia cells from arsenic trioxide-induced caspase-3 activation and apoptosis. Eur J Pharmacol. 2014;736:115–23.
123. Aoki H, Yokoyama H, Yoshioka Y, Ikeda K, Takahashi H, Morita S, et al. Cyclic AMP induces IPC leukemia cell apoptosis via CRE-and CDK-dependent Bim transcription. Cell Death Dis. 2011;2:e237.
124. Wang M, Li Y, Wang R, Wang Z, Chen K, Zhou B, et al. PKA RhoA/Akinase anchoring proteins 10 signaling pathway and the prognosis of colorectal cancer. J Gastroenterol Hepatol. 2015;30:496–503.
125. Huan X, Kong Q, Yin J, Zhang J, Jiang Y. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy. J Hematol Oncol. 2020;13:64.
126. Leipprakum PD, Brattain MG, Black JD, Wang J. TGFβ and IGF1R signaling activates protein kinase A through differential regulation of ezrin phosphorylation in colon cancer cells. J Biol Chem. 2018;293:8242–54.
127. Troiani T, Vecchione L, Martellini E, Casparo P, Costantino S, Buffreda LP, et al. Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. Br J Cancer. 2012;106:1648–59.
128. Xian D, Zhao Y, LncRNA KCNQ1OT1 enhanced the methotrexate resistance of colorectal cancer cells by regulating miR-760/PPP1R1B via the cAMP signaling pathway. J Cell Mol Med. 2019;23:8058–23.
129. Brudvik KW, Paulsen JE, Aalahl EM, Robad T, Tasken K. Protein kinase A antagonist inhibits b-catenin nuclear translocation, c-Myc and COX-2 expression and tumor promotion in APCMin/+ mice. Mol Cancer. 2011;10:149.
132. Mantovani G, Bondioni S, Lania AG, Rodolfo M, Peverelli E, Polentarutti N, et al. High expression of PKA regulatory subunit 1A protein is related to proliferation of human melanoma cells. Oncogene. 2008;27:1834–43.
133. Finger EC, Castellini L, Rankin EB, Vilalta M, Krieg AJ, Jiang D, et al. Hypoxic induction of AKAP12 variant 2 shifts PKA-mediated protein phosphorylation to enhance migration and metastasis of melanoma cells. Proc Natl Acad Sci USA. 2015;112:4441–6.
134. Jian D, Jiang D, Su J, Chen W, Hu X, Kuang Y, et al. Diethylstilbestrol enhances melanogenesis via cAMP–PKA-mediating up-regulation of tyrosinase and MITF in mouse B16 melanoma cells. Steroids. 2011;76:297–304.
135. Huang HC, Chou YC, Wu CY, Chang TM. [8]-Gingerol inhibits melanogenesis in murine melanoma cells through down-regulation of the MAPK and PKA signal pathways. Biochem Biophys Res Commun. 2013;438:375–81.
136. Cho-Chung YS, Nesterova MV. Tumor reversion: protein kinase A isozyme switching. Ann NY Acad Sci. 2005;1058:76–86.
137. Schwede F, Maronde E, Genieser H, Jastorff B. Cyclic nucleotide analogs as biochemical tools and prospective drugs. PharmacoL Ther. 2000;87:199–226.
138. Choi KY, Ahn YH, Ahn HW, Cho YJ, Hong SH. Involvement of Akt2/protein kinase B isozyme switching. Ann NY Acad Sci. 2005;1058:76–86.
139. Matera MG, Page C, Cazzola M. PDE inhibitors currently in early clinical trials for the treatment of asthma. Expert Opin Investig Drugs. 2014;23:1267–75.
140. Goel S, Desai K, Macapinlac M, Wadler S, Goldberg G, Fields A, et al. A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A RI alpha in patients with advanced solid cancers. Invest New Drugs. 2006;24:125–34.
141. Mitton B, Chae HD, Hu K, et al. Small molecule inhibition of cAMP response element binding protein in human acute myeloid leukemia cells. Leukemia. 2016;30:2302–11.
142. Chae HD, Cox N, Dahl GV, Lacayo NJ, Davis KL, Capolicchio S, et al. Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways. Oncotarget. 2017;9:4301–17.
143. Kang X, Cui C, Wang C, Wu G, Chen H, Lu Z, et al. CAMKs support development of acute myeloid leukemia. J Hematol Oncol. 2018;11:30.
144. Insel PA, Zhang L, Murray F, Yokouchi H, Zambon AC. Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger. Acta Physiol (Oxf). 2012;204:277–87.
145. Wilderman A, Guo Y, Divakaruni AS, Perkins G, Zhang L, Murphy AN, et al. Proteomic and metabolic analyses of S49 lymphoma cells reveal novel regulation of mitochondria by cAMP and protein kinase A. J Biol Chem. 2015;290:22274–86.
146. Zambon AC, Wilderman A, Ho A, Insel PA. Increased expression of the pro-apoptotic protein BIM, a mechanism for cAMP/protein kinase A (PKA)-induced apoptosis of immature T cells. J Biol Chem. 2011;286:33260–7.
147. Jewell JL, Fu V, Hong AW, Yu FX, Meng D, Melick CH, et al. GPCR signaling inhibits mTORC1 via PKA phosphorylation of Raptor. Elife. 2019;8:e43038.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.